SOUTH WILLIAMSPORT, Pa., March 19 /PRNewswire/ -- Rapid Pathogen Screening announced the addition of Dr. Uma Mahesh Babu, Ph.D. as the Vice President: Technology and Product Development. Dr. Babu will be responsible for all RPS engineering, technology & product development efforts for all lateral flow immunochromatography products from conception stage through manufacturing.
Dr. Babu has over 20 years of experience in product development. He earned his doctorate degree in Chemistry from the University of Nebraska at Lincoln, Nebraska. He did his post-doctoral fellowship in Immunology at the University of Manitoba in Winnipeg, Canada. He was a Research Associate Professor at Thomas Jefferson University in the department of Biochemistry. He has served as a Director in Research and Development at both small and large companies such as Empyrean Diagnostics, ChemTrak and Johnson and Johnson.
Dr. Babu has successfully developed several rapid Point of Care tests both in the human as well as in the veterinary arena. He has excellent expertise in developing immunoassays and bioassays from conception though feasibility studies, development, QA/QC, commercialization and technical support. He has coauthored several scientific publications and has presented papers at both national and international conferences.
“Dr. Babu is a stellar addition to the RPS Leadership Team,” stated Thomas Orsini, Chief Executive Officer. “His background and knowledge make him a perfect fit to allow RPS to continue its market leadership position in the ocular point of care test market. Dr. Babu will use his extensive experience to lead our on-going development of additional ocular tests.”
About Rapid Pathogen Screening
Rapid Pathogen Screening, Inc. (RPS) develops point-of-care diagnostic devices for ocular diseases. The RPS Adeno Detector(TM), for detection of viral conjunctivitis, is the first in a family of tests.
The FDA cleared and CLIA waived RPS Adeno Detector(TM) is the first true point of care test available for conjunctivitis. It can provide a definitive result in 10 minutes and makes a laboratory confirmation of adenoviral conjunctivitis readily available at the time of the patient exam. The RPS Adeno Detector(TM) can aid health care providers to make an accurate diagnosis, foster patient acceptance of more supportive therapies, identify contagious viral conjunctivitis, and limit spread of disease while simultaneously reducing ocular antibiotic resistance and the cost of unnecessary antibiotics. The test is being used in optometry and ophthalmology offices, military bases, and other points of care across the United States.
Contact: Dan Maloy Rapid Pathogen Screening, Inc. 877-921-0080 maloy@rps-tests.comhttp://www.rps-tests.com
Rapid Pathogen Screening, Inc.
CONTACT: Dan Maloy, Rapid Pathogen Screening, Inc., 1-877-921-0080,maloy@rps-tests.com
Web site: http://www.rps-tests.com/
